Steven Idell is a Respiratory physician affiliated with The University of Texas Health Science Center at Tyler. OpenAlex indexes 355 publications with 8,151 citations (h-index 48).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11937 Us Highway 271
Tyler, TX 757083154
Telephone
903-877-7777Registry record last updated 21 Oct 2016.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
100%Phosphodiesterase 4 Inhibitor100%Daliresp100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 1986–2024 per NIH RePORTER. The latest:
- Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema
University of Texas Hlth Ctr at Tyler
FY2024$524,404R01HL130402 - Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema
University of Texas Hlth Ctr at Tyler
FY2023$535,106R01HL130402 - Delivery of PAI-1-targeted intrapleural fibrinolytic therapy for empyema
University of Texas Hlth Ctr at Tyler
FY2022$535,336R01HL130402
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Caveolin-1–derived peptide limits development of pulmonary fibrosis
Science Translational Medicine
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Philley, MD
The University of Texas Health Science Center at Tyler
James Caccitolo, MD
The University of Texas Health Science Center at Tyler
Jeana Benwill, MD
The University of Texas Health Science Center at Tyler
George Plotkin, MD
The University of Texas Health Science Center at Tyler
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”